History

GAP Peptides, LLC was incorporated in the summer of 2017 with the vision of transforming peptide manufacturing and positively impacting health and wellness around the world.

A patent covering the invention of a System and Method for Solution Phase GAP Peptide Synthesis was issued on March 16, 2021 as U.S. Patent No. 10,947,267.

The proprietary technology offers an alternative to traditional methods of peptide synthesis.  GAP-PS is a novel, green, cost-saving alternative approach for large scale peptide manufacture. Using synthetic organic chemistry methods combined with standard Fmoc chemistry, we developed and optimized synthesis routes for synthetic peptides used in cosmetics, pharma, diagnostics, R&D, nutrition, and other industries.

The current patent portfolio comprises multiple patent families with dozens of patent applications, covering key countries, including the U.S., EPO, Canada, China, Israel, India, Japan, Korea, Hong Kong, and Mexico.

Our clients realized benefit from of GAP-PS applied in early-stage R&D settings in labs at universities and commercial research centers.  Driven by process advantages enabled through GAP-PS, application of the methodology in commercial production settings created new opportunities for companies seeking to revitalize large scale, domestic manufacturing.

GAP Peptides, LLC is a privately held company.